CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤，Version 2.2024，NCCN 肿瘤临床实践指南
英文原题：Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
查看英文原题
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
复发/难治性多发性骨髓瘤（MM）的治疗已发展出多种新选择，包括与第二代蛋白酶体抑制剂（PI）的新型联合方案、第二代免疫调节剂、单克隆抗体、CAR-T 细胞、双特异性抗体、selinexor、venetoclax等。多数MM患者会经历多次缓解和复发，因此需要多线联合治疗。为复发/难治性MM选择治疗方案时，需考虑患者对特定药物类别的耐药状态，并结合年龄及其他合并症等个体因素。NCCN MM指南为新诊断和既往治疗过的MM患者的检查评估、治疗和随访决策提供框架。本文概述NCCN MM指南中针对复发/难治性疾病的建议。
展开英文摘要原文
The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several new options. These include new combinations with second generation proteasome inhibitors (PI); second generation immunomodulators, monoclonal antibodies, CAR T cells, bispecific antibodies, selinexor, venetoclax, and many others. Most patients with MM undergo several cycles of remissions and relapse, and therefore need multiple lines of combination therapies.
Selecting treatment options for relapsed/refractory MM requires consideration of resistance status to specific classes, and patient-specific factors such as age and other comorbidities should be considered. The NCCN Guidelines for MM provide a framework on which to base decisions regarding workup, treatment, and follow-up of newly diagnosed and previously treated MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to relapsed/refractory disease.
论文信息
- 作者
- Kumar SK、Callander NS、Adekola K、Anderson LD Jr、Baljevic M、Baz R、Campagnaro E、Castillo JJ
- 第一作者单位
- Mayo Clinic Comprehensive Cancer Center.
- 通讯作者单位
- National Comprehensive Cancer Network.
- 文献类型
- 临床实践指南
- 期刊
- Journal of the National Comprehensive Cancer Network : JNCCN2023 Dec
- 原文标识
- PubMed 38081133 · DOI 10.6004/jnccn.2023.0061